Literature DB >> 15278306

Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography.

Jong Doo Lee1, Mijin Yun, Jae Myun Lee, Youjeong Choi, Youn-Hee Choi, Ji Su Kim, Se Jong Kim, Kyung Sik Kim, Woo Ick Yang, Young Nyun Park, Kwang-Hyub Han, Woo Jung Lee, Naechun Yoo, Sang Moo Lim, Jeon Han Park.   

Abstract

PURPOSE: 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) scan has been found to reflect tumour aggressiveness and prognosis in various types of cancer. In this study, the gene expression profiles of hepatocellular carcinomas (HCCs) were evaluated to determine whether HCCs with high 18F-FDG uptake have more aggressive biological potential than those with low uptake.
METHODS: Surgical specimens were obtained from ten patients with HCC (six males and four females, age range 38-68 years). The tumour samples were divided into two groups based on the 18F-FDG PET scan findings: high 18F-FDG uptake (n=4) and low 18F-FDG uptake (n=6).
RESULTS: The pathological tumour grade was closely correlated with the 18F-FDG uptake pattern: HCCs with high 18F-FDG uptake were pathologically Edmondson-Steiner grade III, while those with low uptake were either grade II or grade II with a focal area of grade III. The total RNA was extracted from the frozen tissues of all HCCs (n=10) and adjacent non-cancerous tissue (n=7). The gene expression profiles were evaluated using an oligoDNA microarray. The HCCs with high 18F-FDG uptake showed increased expression of 11 genes--including vascular cell adhesion molecule-1, vinexin beta and core 1 UDP-galactose:N-acetylgalactosamine-alpha-R-beta 1,3-galactosyltransferase and the natural killer cell inhibitory receptor--compared to those with low uptake (p<0.005). Nine genes, including regulator of mitotic spindle assembly 1, grb2-related adaptor protein and beta-1,3-n-acetylglucosaminyltransferase, were repressed.
CONCLUSION: Gene expression is closely related to cell survival, cell-to-cell adhesion or cell spreading; therefore, HCCs with high 18F-FDG uptake appear to have more aggressive biological properties than those with low uptake.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278306     DOI: 10.1007/s00259-004-1602-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  39 in total

1.  Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma.

Authors:  S Shiomi; S Nishiguchi; H Ishizu; Y Iwata; N Sasaki; A Tamori; D Habu; T Takeda; S Kubo; H Ochi
Journal:  Am J Gastroenterol       Date:  2001-06       Impact factor: 10.864

2.  Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors.

Authors:  Oliver Wirths; Anke Waha; Sascha Weggen; Peter Schirmacher; Thomas Kühne; Cynthia G Goodyer; Steffen Albrecht; Dietrich Von Schweinitz; Torsten Pietsch
Journal:  Lab Invest       Date:  2003-03       Impact factor: 5.662

3.  Grap-2, a novel RET binding protein, is involved in RET mitogenic signaling.

Authors:  Leopold Ludwig; Heidi Kessler; Cuong Hoang-Vu; Henning Dralle; Guido Adler; Bernhard O Boehm; Roland M Schmid
Journal:  Oncogene       Date:  2003-08-14       Impact factor: 9.867

4.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

5.  Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis.

Authors:  Norio Iizuka; Masaaki Oka; Hisafumi Yamada-Okabe; Naohide Mori; Takao Tamesa; Toshimasa Okada; Norikazu Takemoto; Kiichiro Hashimoto; Akira Tangoku; Kenji Hamada; Hironobu Nakayama; Takanobu Miyamoto; Shunji Uchimura; Yoshihiko Hamamoto
Journal:  Oncogene       Date:  2003-05-15       Impact factor: 9.867

6.  Hepatocellular carcinoma: role of estrogen receptors in the liver.

Authors:  Erica Villa; Antonella Grottola; Alessandra Colantoni; Nicola De Maria; Paola Buttafoco; Ilva Ferretti; Federico Manenti
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

7.  Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice.

Authors:  Marie K Lindberg; Sofia Movérare; Stanko Skrtic; Hui Gao; Karin Dahlman-Wright; Jan-Ake Gustafsson; Claes Ohlsson
Journal:  Mol Endocrinol       Date:  2003-02

8.  In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.

Authors:  T Torizuka; N Tamaki; T Inokuma; Y Magata; S Sasayama; Y Yonekura; A Tanaka; Y Yamaoka; K Yamamoto; J Konishi
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

Review 9.  Regulated assembly of the mitotic spindle: a perspective from two ends.

Authors:  Lynne Cassimeris; Robert V Skibbens
Journal:  Curr Issues Mol Biol       Date:  2003-07       Impact factor: 2.081

10.  FDG-PET. A possible prognostic factor in head and neck cancer.

Authors:  W Halfpenny; S F Hain; L Biassoni; M N Maisey; J A Sherman; M McGurk
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

View more
  33 in total

1.  Involvement of mitophagy in oncogenic K-Ras-induced transformation: overcoming a cellular energy deficit from glucose deficiency.

Authors:  June-Hyung Kim; Hee Young Kim; Young-Kyoung Lee; Young-Sil Yoon; Wei Guang Xu; Joon-Kee Yoon; Sung-E Choi; Young-Gyu Ko; Min-Jung Kim; Su-Jae Lee; Hee-Jung Wang; Gyesoon Yoon
Journal:  Autophagy       Date:  2011-10-01       Impact factor: 16.016

2.  18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Myeong Jun Song; Si Hyun Bae; Sung Won Lee; Do Sun Song; Hee Yeon Kim; Ie Ryung Yoo; Joon-Il Choi; Young June Lee; Ho Jong Chun; Hae Giu Lee; Jong Young Choi; Seung Kew Yoon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

3.  Adding variables to complexity. Molecular imaging and molecular biology: a no-longer-secret liaison in NETs.

Authors:  Annibale Versari; Alessia Ciarrocchi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08       Impact factor: 9.236

4.  Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium.

Authors:  Orazio Schillaci; Nicoletta Urbano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04       Impact factor: 9.236

Review 5.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

Review 6.  The emerging role of positron emission tomography in hepatocellular carcinoma.

Authors:  Suraiya R Dubash; Oluwagbemiga A Idowu; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-04-27

Review 7.  Radiolabelled RGD peptides for imaging and therapy.

Authors:  F C Gaertner; H Kessler; H-J Wester; M Schwaiger; A J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 8.  Understanding the tumor microenvironment and radioresistance by combining functional imaging with global gene expression.

Authors:  Mark W Dewhirst; Jen-Tsan Chi
Journal:  Semin Radiat Oncol       Date:  2013-10       Impact factor: 5.934

9.  Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT: a multicenter retrospective cohort study.

Authors:  Seung Hyup Hyun; Jae Seon Eo; Bong-Il Song; Jeong Won Lee; Sae Jung Na; Il Ki Hong; Jin Kyoung Oh; Yong An Chung; Tae-Sung Kim; Mijin Yun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-22       Impact factor: 9.236

10.  Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.

Authors:  Daiki Yamashige; Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Satoshi Okubo; Nozomu Muraishi; Akira Kajiwara; Soichi Iritani; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Oncology       Date:  2020-11-18       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.